Bionano Genomics, Inc. (NASDAQ:BNGO – Get Free Report) hit a new 52-week low during trading on Monday . The company traded as low as $6.04 and last traded at $6.02, with a volume of 160997 shares trading hands. The stock had previously closed at $7.29.
Wall Street Analyst Weigh In
Separately, LADENBURG THALM/SH SH cut shares of Bionano Genomics from a “buy” rating to a “neutral” rating in a research note on Friday, November 15th.
View Our Latest Analysis on Bionano Genomics
Bionano Genomics Stock Performance
Institutional Investors Weigh In On Bionano Genomics
Large investors have recently added to or reduced their stakes in the business. Geode Capital Management LLC lifted its holdings in Bionano Genomics by 47.3% in the 3rd quarter. Geode Capital Management LLC now owns 882,854 shares of the company’s stock valued at $401,000 after purchasing an additional 283,639 shares in the last quarter. GSA Capital Partners LLP purchased a new position in Bionano Genomics in the 3rd quarter valued at about $46,000. Finally, Carret Asset Management LLC lifted its holdings in shares of Bionano Genomics by 89.0% during the 3rd quarter. Carret Asset Management LLC now owns 85,055 shares of the company’s stock worth $39,000 after acquiring an additional 40,055 shares during the period. 11.35% of the stock is owned by institutional investors and hedge funds.
Bionano Genomics Company Profile
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
Read More
- Five stocks we like better than Bionano Genomics
- What is a Low P/E Ratio and What Does it Tell Investors?
- Sizing Up a New Opportunity for NVIDIA Investors
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Do ETFs Pay Dividends? What You Need to Know
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.